RE:RE:RE:RE:RE:Seeking Alpha on recent THTX development You are right. They know a lot more than they have published on Tesamorelin and the liver. At RD day Grinspoon mentioned he thought that showing positive cardiovascular readings along with the fat resolution was important. In saying that, you knew that he knew. His current large study is, I believe , a statin-based trial for HIV patients but I vaguely recall his colleague Tamara Stanley has done or is doing some work around the metabolism and CV readings with Egrifta on HIV. Maybe it's another one of the extension studies. The smaller liver study done prior to the Lancet one had very good CV readings attached to it. The Lancet study only showed the various CV indicators like HCL, etc... did not get any worse. So I guess you could say the additional benefits for CV are somewhere between good and neutral, but further study may elucidate that effect more. Madrigal definitely added a lot more analysis of the positively effected subgroup so maybe if THTX only looks at the high response cohort it could show something similar. But Grinspoon is definitely targeted at that and I'm sure it will be in the design of the trial as an additional reading, not an endpoint clearly
jeffm34 wrote: There are all kinds of liver diseases or medical conditions related to the liver. What if Egrifta is helpful in one or more of those. Like diabetes or high chloresterol? I believe MDGL is trying to show that their fat burning drug Resmetiron also helps in these areas. What if Egrifta has some fo the the same attributes?
I don't believe it will be useful in Diabetes.
"administration of pharmacological doses of rhGH is associated with a variety of adverse effects, including hyperglycemia, insulin resistance"
A study was done with Tesamorelin to see if it had simialar effects, which luckily it did not. It may be beneficial in lowering cholesterol though.
No significant differences were observed between groups in relative insulin response over the 12-week treatment period. At Week 12, fasting glucose, HbA1c and overall diabetes control were not significantly different between groups. In addition, relevant modifications in diabetes medications were similar between groups. Total cholesterol (-0.3±0.6 mmol/L) and non-HDL cholesterol (-0.3±0.5 mmol/L) significantly decreased from baseline to Week 12 in the tesamorelin 2 mg group (p<0.05 vs. placebo). No patient discontinued the study due to loss of diabetes control.